|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-16
|
|
pubmed:abstractText |
NGR-hTNF consists of human tumour necrosis factor-alpha (hTNF-alpha) fused to the tumour-homing peptide NGR, a ligand of an aminopeptidase N/CD13 isoform, which is overexpressed on endothelial cells of newly formed tumour blood vessels. NGR-TNF showed a biphasic dose-response curve in preclinical models. This study exploring the low-dose range aimed to define safety and optimal biological dose of NGR-hTNF.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
pubmed-author:BordignonClaudioC,
pubmed-author:BorriAnnaA,
pubmed-author:BruzziPaoloP,
pubmed-author:Caligaris-CappioFedericoF,
pubmed-author:CitterioGiovanniG,
pubmed-author:CortiAngeloA,
pubmed-author:De CobelliFrancescoF,
pubmed-author:Del MaschioAlessandroA,
pubmed-author:Dell'AcquaFlavioF,
pubmed-author:DonadoniGiovanniG,
pubmed-author:EspositoAntonioA,
pubmed-author:GregorcVanesaV,
pubmed-author:LambiaseAntonioA,
pubmed-author:RossoniGildaG,
pubmed-author:ScifoPaolaP,
pubmed-author:SpreaficoAnnaA,
pubmed-author:TroysiAntonellaA,
pubmed-author:VitaliGiordanoG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
198-206
|
|
pubmed:meshHeading |
pubmed-meshheading:19900802-Adult,
pubmed-meshheading:19900802-Aged,
pubmed-meshheading:19900802-Angiogenesis Inhibitors,
pubmed-meshheading:19900802-Antineoplastic Agents,
pubmed-meshheading:19900802-Dose-Response Relationship, Drug,
pubmed-meshheading:19900802-Drug Administration Schedule,
pubmed-meshheading:19900802-Female,
pubmed-meshheading:19900802-Humans,
pubmed-meshheading:19900802-Magnetic Resonance Imaging,
pubmed-meshheading:19900802-Male,
pubmed-meshheading:19900802-Middle Aged,
pubmed-meshheading:19900802-Neoplasms,
pubmed-meshheading:19900802-Recombinant Fusion Proteins,
pubmed-meshheading:19900802-Treatment Outcome,
pubmed-meshheading:19900802-Tumor Markers, Biological,
pubmed-meshheading:19900802-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
|
|
pubmed:affiliation |
Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
